0000000000320722

AUTHOR

Gallo M

showing 5 related works from this author

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

2016

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for th…

0301 basic medicineOncologyCancer ResearchmTOR inhibitorEndocrinology Diabetes and MetabolismNeuroendocrine tumorsAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumoursneuroendocrine tumourTreatment resistanceMTOR inhibitorsTumorMedical treatmentTOR Serine-Threonine KinasesDiscovery and development of mTOR inhibitorsResponse to treatmentPatient managementDiabetes and MetabolismNeuroendocrine TumorsOncology030220 oncology & carcinogenesisResponse to treatmentNeuroendocrine TumorHumanMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Endocrinology Diabetes and Metabolism; Oncology; Endocrinology; Cancer ResearchDiagnostic Imagingmedicine.medical_specialtyProtein Kinase InhibitorEarly detectionpredictorAntineoplastic AgentsMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Endocrinology; Oncology; Cancer Research; Endocrinology Diabetes and MetabolismBiologyNO03 medical and health sciencesmTOR inhibitors; neuroendocrine tumours; predictors; response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine KinasesInternal medicineBiomarkers TumormedicineAnimalsHumansmTOR inhibitorsneuroendocrine tumourspredictorsresponse to treatmentProtein Kinase InhibitorsmTOR inhibitors neuroendocrine tumours predictors response to treatmentAnimalPredictorsmedicine.disease030104 developmental biologyImmunologyBiomarkersResource utilizationEndocrine-Related Cancer
researchProduct

Factors influencing pain, physical function and social functioning in patients with osteoarthritis in southern Italy.

2004

researchProduct

Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study

2004

Ostheoarthritis (OA) is a social disease characterized by pain, inflammation and stiffness due to an involvement of articular cartilage, soft tissues and bone. OA is the most common rheumatic disease, every age can be affected but prevalence increases dramatically with age with a greater incidence in subjects between 40 and 50 years of age. Hip OA has an important correlation with weight, genetic factors, sex, previous traumas, occupational factors and age. People older than 35 have a prevalence of Hip OA of 10,8% that becomes 35,4% in people older than 85. Knee OA has a great correlation with weight, life style and physical activity. An Italian study has demonstrated that the prevalence of…

Osteoarthritis coxibs knee hip prevalence
researchProduct

Azotofissatori liberi e oligonitrofili da suoli sottoposti a pratiche agronomiche biologiche.

2006

researchProduct

Albumin replacement in patients with severe sepsis or septic shock.

2014

BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with or…

Malemedicine.medical_specialtyALBUMIN SEPSIS SEVERE SEPSIS SEPTIC SHOCKSepsiSerum albuminSettore MED/41 - AnestesiologiaAged; Albumins; Female; Humans; Isotonic Solutions; Male; Middle Aged; Rehydration Solutions; Sepsis; Serum Albumin; Shock Septic; Survival Rate; Treatment OutcomeSepsisIntensive careAlbuminsSepsismedicineHumansalbumin replacementSurvival rateSerum AlbuminIsotonic SolutionAgedAged; Albumins; Female; Humans; Isotonic Solutions; Male; Middle Aged; Rehydration Solutions; Sepsis; Serum Albumin; Shock Septic; Survival Rate; Treatment Outcome; Medicine (all)SEPSISbiologybusiness.industrySeptic shockRehydration SolutionSepticMedicine (all)AlbuminSEPTIC SHOCKOrgan dysfunctionAlbuminShockGeneral MedicineMiddle Agedmedicine.diseaseShock SepticSurgerySurvival RateTreatment OutcomeAnesthesiaRelative riskRehydration Solutionsbiology.proteinFemalemedicine.symptomIsotonic SolutionsbusinessHuman
researchProduct